PPARD: A Potential Drug Target and Biomarker for the Treatment of Inflammatory Diseases

Target Name: PPARD

NCBI ID: G5467

PPARD

PPARD: A Potential Drug Target and Biomarker for the Treatment of Inflammatory Diseases

PPARD (4-phenyl-1-butanone) is a naturally occurring compound that has been found to have anti-inflammatory properties. Despite its potential benefits,PPARD has not yet been developed as a drug target or biomarker. However, the recent studies on the role of PPARD in the treatment of inflammatory diseases have raised its profile and highlighted its potential as a drug target and biomarker. In this article, we will discuss the current state of PPARD research and its potential as a drug target and biomarker.

The Importance of Inflammatory Diseases

Inflammatory diseases are a significant public health issue that affect millions of people worldwide. These diseases cause chronic pain, damage to various organs, and lead to an increased risk of death. Some of the most common inflammatory diseases include rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease. These diseases are associated with chronic inflammation that can lead to the activation of immune cells, resulting in the production of pro-inflammatory compounds.

The Need for Effective Treatments

The treatment of inflammatory diseases is a ongoing challenge. While several medications have been developed to treat these diseases, their effectiveness is limited. The lack of effective treatments for these diseases has led to a significant burden on healthcare systems and has resulted in a high rate of disease-related morbidity and mortality.

The Potential of PPARD as a Drug Target

PPARD has been found to have anti-inflammatory properties that could make it an effective drug target for the treatment of inflammatory diseases. The compound has been shown to inhibit the production of pro-inflammatory compounds in immune cells. This has led to the potential for PPARD to be used as a treatment for inflammatory diseases.

PPARD's anti-inflammatory properties have been shown to be effective in animal models of rheumatoid arthritis and psoriatic arthritis. Studies have shown that treatment with PPARD can reduce inflammation and improve the symptoms of these diseases. Additionally, PPARD has been shown to have anti-inflammatory properties in human samples, which suggests that it may be effective in treating human inflammatory diseases.

The Potential of PPARD as a Biomarker

PPARD has also been shown to be a potential biomarker for the diagnosis and monitoring of inflammatory diseases. The compound has been found to be significantly elevated in the blood samples of people with rheumatoid arthritis and psoriatic arthritis. This suggests that PPARD could be used as a biomarker for the diagnosis and monitoring of these diseases.

Conclusion

In conclusion, PPARD has the potential to be a drug target and biomarker for the treatment of inflammatory diseases. The compound's anti-inflammatory properties make it an attractive candidate for use as a potential therapeutic agent. Further research is needed to determine the effectiveness of PPARD as a drug and to develop biomarkers for its use. If PPARD is shown to be effective in the treatment of inflammatory diseases, it could have a significant impact on healthcare and be a valuable addition to the treatment options available for these diseases.

Protein Name: Peroxisome Proliferator Activated Receptor Delta

Functions: Ligand-activated transcription factor key mediator of energy metabolism in adipose tissues (PubMed:35675826). Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Has a preference for poly-unsaturated fatty acids, such as gamma-linoleic acid and eicosapentanoic acid. Once activated by a ligand, the receptor binds to promoter elements of target genes. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as transcription activator for the acyl-CoA oxidase gene. Decreases expression of NPC1L1 once activated by a ligand

The "PPARD Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPARD comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets